DermatologyNews.net

Dermatology Xagena

Search results for "Ixekizumab"

Phase II data, published in the New England Journal of Medicine ( NEJM ), have showen that Ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe p ...


The New England Journal of Medicine ( NEJM ) has published detailed results from three pivotal phase 3 studies, UNCOVER-1, UNCOVER-2 and UNCOVER-3, that have demonstrated the efficacy and safety of Ix ...